295 related articles for article (PubMed ID: 20439706)
1. Peptide antagonism as a mechanism for NK cell activation.
Fadda L; Borhis G; Ahmed P; Cheent K; Pageon SV; Cazaly A; Stathopoulos S; Middleton D; Mulder A; Claas FH; Elliott T; Davis DM; Purbhoo MA; Khakoo SI
Proc Natl Acad Sci U S A; 2010 Jun; 107(22):10160-5. PubMed ID: 20439706
[TBL] [Abstract][Full Text] [Related]
2. Large spectrum of HLA-C recognition by killer Ig-like receptor (KIR)2DL2 and KIR2DL3 and restricted C1 SPECIFICITY of KIR2DS2: dominant impact of KIR2DL2/KIR2DS2 on KIR2D NK cell repertoire formation.
David G; Djaoud Z; Willem C; Legrand N; Rettman P; Gagne K; Cesbron A; Retière C
J Immunol; 2013 Nov; 191(9):4778-88. PubMed ID: 24078689
[TBL] [Abstract][Full Text] [Related]
3. Allelic variation in KIR2DL3 generates a KIR2DL2-like receptor with increased binding to its HLA-C ligand.
Frazier WR; Steiner N; Hou L; Dakshanamurthy S; Hurley CK
J Immunol; 2013 Jun; 190(12):6198-208. PubMed ID: 23686481
[TBL] [Abstract][Full Text] [Related]
4. Structural plasticity of KIR2DL2 and KIR2DL3 enables altered docking geometries atop HLA-C.
Moradi S; Stankovic S; O'Connor GM; Pymm P; MacLachlan BJ; Faoro C; Retière C; Sullivan LC; Saunders PM; Widjaja J; Cox-Livingstone S; Rossjohn J; Brooks AG; Vivian JP
Nat Commun; 2021 Apr; 12(1):2173. PubMed ID: 33846289
[TBL] [Abstract][Full Text] [Related]
5. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
6. Peptide selectivity discriminates NK cells from KIR2DL2- and KIR2DL3-positive individuals.
Cassidy S; Mukherjee S; Myint TM; Mbiribindi B; North H; Traherne J; Mulder A; Claas FH; Purbhoo MA; Das J; Khakoo SI
Eur J Immunol; 2015 Feb; 45(2):492-500. PubMed ID: 25359276
[TBL] [Abstract][Full Text] [Related]
7. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3.
Moesta AK; Norman PJ; Yawata M; Yawata N; Gleimer M; Parham P
J Immunol; 2008 Mar; 180(6):3969-79. PubMed ID: 18322206
[TBL] [Abstract][Full Text] [Related]
8. Spatial Clustering of Receptors and Signaling Molecules Regulates NK Cell Response to Peptide Repertoire Changes.
Mbiribindi B; Mukherjee S; Wellington D; Das J; Khakoo SI
Front Immunol; 2019; 10():605. PubMed ID: 31024524
[TBL] [Abstract][Full Text] [Related]
9. Mutation at positively selected positions in the binding site for HLA-C shows that KIR2DL1 is a more refined but less adaptable NK cell receptor than KIR2DL3.
Hilton HG; Vago L; Older Aguilar AM; Moesta AK; Graef T; Abi-Rached L; Norman PJ; Guethlein LA; Fleischhauer K; Parham P
J Immunol; 2012 Aug; 189(3):1418-30. PubMed ID: 22772445
[TBL] [Abstract][Full Text] [Related]
10. HLA reduces killer cell Ig-like receptor expression level and frequency in a humanized mouse model.
van Bergen J; Thompson A; van Pel M; Retière C; Salvatori D; Raulet DH; Trowsdale J; Koning F
J Immunol; 2013 Mar; 190(6):2880-5. PubMed ID: 23390293
[TBL] [Abstract][Full Text] [Related]
11. Stable Frequencies of HLA-C
Ziegler MC; Grañana FB; Garcia-Beltran WF; Schulze Zur Wiesch J; Hoffmann C; Rechtien A; Lunemann S; Altfeld M
Front Immunol; 2018; 9():2361. PubMed ID: 30386333
[TBL] [Abstract][Full Text] [Related]
12. Quantity of HLA-C surface expression and licensing of KIR2DL+ natural killer cells.
Charoudeh HN; Schmied L; Gonzalez A; Terszowski G; Czaja K; Schmitter K; Infanti L; Buser A; Stern M
Immunogenetics; 2012 Oct; 64(10):739-45. PubMed ID: 22772778
[TBL] [Abstract][Full Text] [Related]
13. Polymorphic HLA-C Receptors Balance the Functional Characteristics of KIR Haplotypes.
Hilton HG; Guethlein LA; Goyos A; Nemat-Gorgani N; Bushnell DA; Norman PJ; Parham P
J Immunol; 2015 Oct; 195(7):3160-70. PubMed ID: 26311903
[TBL] [Abstract][Full Text] [Related]
14. Sequence variations in HIV-1 p24 Gag-derived epitopes can alter binding of KIR2DL2 to HLA-C*03:04 and modulate primary natural killer cell function.
van Teijlingen NH; Hölzemer A; Körner C; García-Beltrán WF; Schafer JL; Fadda L; Suscovich TJ; Brander C; Carrington M; Evans DT; van Baarle D; Altfeld M
AIDS; 2014 Jun; 28(10):1399-408. PubMed ID: 24785948
[TBL] [Abstract][Full Text] [Related]
15. KIR downregulation by IL-12/15/18 unleashes human NK cells from KIR/HLA-I inhibition and enhances killing of tumor cells.
Ewen EM; Pahl JHW; Miller M; Watzl C; Cerwenka A
Eur J Immunol; 2018 Feb; 48(2):355-365. PubMed ID: 29105756
[TBL] [Abstract][Full Text] [Related]
16. Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands.
Yu J; Heller G; Chewning J; Kim S; Yokoyama WM; Hsu KC
J Immunol; 2007 Nov; 179(9):5977-89. PubMed ID: 17947671
[TBL] [Abstract][Full Text] [Related]
17. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition.
Winter CC; Gumperz JE; Parham P; Long EO; Wagtmann N
J Immunol; 1998 Jul; 161(2):571-7. PubMed ID: 9670929
[TBL] [Abstract][Full Text] [Related]
18. Analyses of HLA-C-specific KIR repertoires in donors with group A and B haplotypes suggest a ligand-instructed model of NK cell receptor acquisition.
Schönberg K; Sribar M; Enczmann J; Fischer JC; Uhrberg M
Blood; 2011 Jan; 117(1):98-107. PubMed ID: 20935255
[TBL] [Abstract][Full Text] [Related]
19. The Education of NK Cells Determines Their Responsiveness to Autologous HIV-Infected CD4 T Cells.
Kiani Z; Dupuy FP; Bruneau J; Lebouché B; Retière C; Geraghty DE; Bernard NF
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511383
[TBL] [Abstract][Full Text] [Related]
20. Human NK cells licensed by killer Ig receptor genes have an altered cytokine program that modifies CD4+ T cell function.
Lin L; Ma C; Wei B; Aziz N; Rajalingam R; Yusung S; Erlich HA; Trachtenberg EA; Targan SR; McGovern DP; Heath JR; Braun J
J Immunol; 2014 Jul; 193(2):940-9. PubMed ID: 24935928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
